Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.
about
Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosisHypersensitivity Responses in the Central Nervous SystemFriends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative DiseasesMultiple sclerosis as a vascular diseaseThe mechanism of action of interferon-β in relapsing multiple sclerosisPermeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosisComplementary and alternative medicine for the treatment of multiple sclerosisMatrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis.The role of TNFalpha and lymphotoxin in demyelinating disease.Long-term expression of tissue-inhibitor of matrix metalloproteinase-1 in the murine central nervous system does not alter the morphological and behavioral phenotype but alleviates the course of experimental allergic encephalomyelitisPathogenic implications of iron accumulation in multiple sclerosis.Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.Naturally occurring disk herniation in dogs: an opportunity for pre-clinical spinal cord injury researchMatrix metalloproteinases and neuroinflammation in multiple sclerosis.Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrierLeukocyte transmigration across endothelial and extracellular matrix protein barriers in liver ischemia/reperfusion injury.Feasibility and safety of intrathecal transplantation of autologous bone marrow mesenchymal stem cells in horses.Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis.Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis.The potential use of MMP inhibitors to treat CNS diseases.CCR2(+)CCR5(+) T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis.Pain in experimental autoimmune encephalitis: a comparative study between different mouse models.Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis PatientsMatrix metalloproteinase levels in early HIV infection and relation to in vivo brain status.Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders.Differential temporal expression of matrix metalloproteinases after spinal cord injury: relationship to revascularization and wound healingSecondary Hematoma Expansion and Perihemorrhagic Edema after Intracerebral Hemorrhage: From Bench Work to Practical Aspects.Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity.Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview.The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomasDiscovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation.Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.Treatment of experimental autoimmune encephalomyelitis with a neurotropic alphavirus vector expressing tissue inhibitor of metalloproteinase-2.CCL27: Novel Cytokine with Potential Role in Pathogenesis of Multiple SclerosisProfiling of metalloprotease activities in cerebrospinal fluids of patients with neoplastic meningitis.Transcriptional mechanisms underlying sensitization of peripheral sensory neurons by granulocyte-/granulocyte-macrophage colony stimulating factors.Association of plasminogen activators and matrix metalloproteinase-9 proteolytic cascade with blood-CNS barrier damage of angiostrongyliasis.Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules.
P2860
Q21144285-08E863B1-5CB1-4F26-9418-12832F9AA7FFQ26779177-450A8C75-3803-40EA-A017-E74D505E41F4Q26779933-E3877846-860B-45AD-AE37-56D3BA138980Q28239335-1DAC0022-C185-4F79-BF62-C038B9116D9EQ28239752-3B444F5F-E549-4BCE-8B3D-FB9A8430D006Q28265269-97DD41B8-2DBD-4762-A8C0-28D1DA97F451Q29031018-20F702A2-09BD-48C4-9958-DED836301B56Q30486651-5B9E4EF6-6D9A-4DD2-BF5A-70FB16A31088Q33782397-C565D480-3A17-404D-B71D-0DE4EC89AA46Q34033395-716365CF-4AF4-450C-980E-1246084CD159Q34049616-F95AC685-5CDA-4CDC-AADE-E6A8F276A05CQ34109028-A39C91F1-AE7E-4F94-B74E-15AC1B3D89A8Q34718044-4CCCEFE0-567A-42EE-B4A4-1AE14612FAFEQ34757608-0211B7DC-2496-47F4-9463-5948D7F6FDABQ35017633-1BE7449D-0CF3-44F5-8736-950CFCD89388Q35136280-77C54BD5-815E-4AD6-8F35-B6280C8D4243Q35167030-50AA714F-2D57-463F-80E9-4877E0C2BEABQ35204364-3DDEEFB4-0F03-4007-BEE1-0F9DF82F3156Q35987823-A7D84DC9-C8FE-4488-A2EC-CCC798DD113FQ36142537-B9B16425-B532-4C60-BACF-CE4D96AEB541Q36181275-4CCFB5F4-180A-45E3-B189-BF239D87F3CFQ36393406-17E440AE-BB55-491A-A2A0-D1AA34FAB02AQ36639036-D6E2FBE4-8621-4356-8919-FC33E0E84B80Q37009992-D12D4BC2-DB1F-4E05-9C4D-29BAA5722D6FQ37171985-4BC8FD40-64F1-456B-8017-802DF2A5AE47Q37283984-227D6062-5707-4D52-988D-341FFDC8125FQ37456857-F6B7F198-F047-4E9F-9999-59AA0A13DE1EQ37471968-EFAF3099-EA26-4C76-AAB9-507EBF83C83BQ37740548-53A6D842-1070-4868-9540-B3F877D68442Q37755142-E066CCC8-D6B0-46E5-B2C9-D9B1EA25C0F9Q38134015-1BC5CA29-BE3A-4425-B3C1-FFA1F25ADBBDQ38136195-49DD0727-9ECD-4D34-904B-B9E7FC5F6E6BQ38634770-BF9D4E1E-343C-4281-B7FD-2CEE34B842EEQ38870841-304C3ED3-5A3C-4D11-9EA3-53FB37DFFBEFQ40513621-037854B9-BAA6-4881-B897-1567F24DBDA0Q40620665-B9C89772-B316-44FB-9474-1BC01D53B626Q41395645-6D62D1A8-1E8A-4517-BA31-061C6BD15728Q42844654-281E27EE-5CD1-41F8-BD5C-790AB5C2666EQ43488684-766D97B5-1BFC-4089-8CEC-F63B34B56196Q43577432-289057B3-C8E6-4EC9-9FF3-B0DB6B2D6FD3
P2860
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Matrix metalloproteinase-9 (ge ...... phases of multiple sclerosis.
@en
type
label
Matrix metalloproteinase-9 (ge ...... phases of multiple sclerosis.
@en
prefLabel
Matrix metalloproteinase-9 (ge ...... phases of multiple sclerosis.
@en
P2093
P356
P1433
P1476
Matrix metalloproteinase-9 (ge ...... phases of multiple sclerosis.
@en
P2093
P304
P356
10.1093/BRAIN/121.12.2327
P407
P478
121 ( Pt 12)
P577
1998-12-01T00:00:00Z